BR0207749A - Bactérias do ácido láctico como agentes para tratar e prevenir alergias - Google Patents

Bactérias do ácido láctico como agentes para tratar e prevenir alergias

Info

Publication number
BR0207749A
BR0207749A BR0207749-3A BR0207749A BR0207749A BR 0207749 A BR0207749 A BR 0207749A BR 0207749 A BR0207749 A BR 0207749A BR 0207749 A BR0207749 A BR 0207749A
Authority
BR
Brazil
Prior art keywords
lactic acid
acid bacteria
agents
treat
prevent allergies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
BR0207749-3A
Other languages
English (en)
Inventor
Beda M Stadler
Monique Vogel
Jacques-Edouard Germond
Rodolph Fritsche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Technique Produits Nestle
Nestle SA
Original Assignee
Assistance Technique Produits Nestle
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Technique Produits Nestle, Nestle SA filed Critical Assistance Technique Produits Nestle
Publication of BR0207749A publication Critical patent/BR0207749A/pt
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"BACTéRIAS DO áCIDO LáCTICO COMO AGENTES PARA TRATAR E PREVENIR ALERGIAS". A presente invenção pertence às cepas de bactérias do ácido láctico capazes de reduzir uma tendência do indivíduo à reação alérgica contra uma variedade de diferentes alérgenos. Em particular, a presente invenção refere-se as cepas recombinantes de bactérias do ácido láctIco que expressam polipeptídeos de superfície que incluem peptídeos ou fragmentos de anticorpo agindo como imitadores para pelo menos uma parte da região F~ c~ das moléculas de IgE. A invenção também pertence às composições farmacêuticas ou de alimento contendo os referidos microorganismos ou frações ativas destes.
BR0207749-3A 2001-03-02 2002-03-04 Bactérias do ácido láctico como agentes para tratar e prevenir alergias Withdrawn BR0207749A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105138A EP1239032A1 (en) 2001-03-02 2001-03-02 Lactic acid bacteria as agents for treating and preventing allergy
PCT/EP2002/002326 WO2002086102A1 (en) 2001-03-02 2002-03-04 Lactic acid bacteria as agents for treating and preventing allergy

Publications (1)

Publication Number Publication Date
BR0207749A true BR0207749A (pt) 2004-06-01

Family

ID=8176657

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207749-3A Withdrawn BR0207749A (pt) 2001-03-02 2002-03-04 Bactérias do ácido láctico como agentes para tratar e prevenir alergias

Country Status (17)

Country Link
US (1) US7235395B2 (pt)
EP (2) EP1239032A1 (pt)
JP (1) JP2004528034A (pt)
KR (2) KR20030082950A (pt)
CN (1) CN1505678A (pt)
AR (1) AR035761A1 (pt)
AU (1) AU2002256639B2 (pt)
BR (1) BR0207749A (pt)
CA (1) CA2438833A1 (pt)
IL (1) IL157468A0 (pt)
MX (1) MXPA03007881A (pt)
NO (1) NO20033796L (pt)
NZ (1) NZ527861A (pt)
PL (1) PL367208A1 (pt)
RU (1) RU2312892C2 (pt)
WO (1) WO2002086102A1 (pt)
ZA (1) ZA200307680B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112773A1 (fr) * 2003-04-24 2004-12-29 Shin-Jen Shiao Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US8252314B2 (en) 2004-09-24 2012-08-28 Hill's Pet Nutrition, Inc. Hypoallergenic composition
JP4974881B2 (ja) * 2005-03-03 2012-07-11 株式会社明治 免疫機能調整剤
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
JP2007300849A (ja) * 2006-05-11 2007-11-22 Oji Paper Co Ltd ペットフード
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CN102028224B (zh) * 2007-06-21 2012-12-26 东宇生物科技股份有限公司 抗过敏的乳酸菌
KR100913405B1 (ko) * 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물
JP5150722B2 (ja) 2008-04-25 2013-02-27 亀田製菓株式会社 抗アレルギー作用を有する新規乳酸菌と、該乳酸菌を含む抗アレルギー剤、食品及び医薬品組成物と、前記抗アレルギー剤の製造方法
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
JP2012502026A (ja) * 2008-09-04 2012-01-26 オーエム ファルマ ラクトバチルス属細菌の免疫調節抽出物及びその製造法と使用法
US20100055082A1 (en) * 2008-09-04 2010-03-04 Jacques Alain Bauer Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
CA2761573A1 (en) * 2009-05-11 2010-11-18 Nestec S.A. Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CA2770099A1 (en) * 2009-08-18 2011-02-24 Nestec S.A. A nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children.
KR20130041164A (ko) 2010-07-09 2013-04-24 스미또모 가가꾸 가부시끼가이샤 올레핀 산화물의 제조 방법
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
KR102038679B1 (ko) * 2018-01-12 2019-10-30 (주)지아이이노베이션 프로바이오틱스 및 IgE에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도
WO2024081219A1 (en) 2022-10-14 2024-04-18 Csp Technologies, Inc. Container and method for storing and stabilizing moisture sensitive products

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242821A (en) 1989-07-10 1993-09-07 Valio, Finnish Co-Operative Dairies' Association Lactococcus promoter and signal sequences for expression in bacteria
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
AU652920B2 (en) 1990-08-30 1994-09-15 Valio Ltd. Promoter probe vectors, able to replicate in E.coli, B.subtilis, lactococci and lactobacillus as well as uses thereof
GB9125695D0 (en) 1991-12-03 1992-01-29 Mastavac Limited Medical preparations
GB9400650D0 (en) * 1994-01-14 1994-03-09 Smithkline Beecham Biolog Expression of surface lazer proteins
AU2149495A (en) 1995-04-11 1996-10-30 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
ES2190799T5 (es) * 1996-03-01 2008-08-16 Novartis Ag Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia.
JPH09234078A (ja) 1996-03-04 1997-09-09 Meiji Milk Prod Co Ltd 乳酸菌用分泌ベクター及び該ベクターを用いたタンパク質の製造方法
NZ334521A (en) * 1996-09-06 2000-03-27 Bioteknologisk Inst A lactic acid bacterial regulatable expression system
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP2004514424A (ja) * 2000-09-25 2004-05-20 ソシエテ　デ　プロデユイ　ネツスル　ソシエテ　アノニム アレルギー反応を起こす個人の傾向を減少させることができる乳酸菌
EP1356073B1 (en) * 2000-10-20 2009-11-25 Bioneer A/S Fermentation method for production of heterologous gene products in lactic acid bacteria
EP1343894A4 (en) * 2000-11-02 2005-05-04 Univ Singapore AOPB GENE, PROTEIN, HOMOLOGISTS, FRAGMENTS AND VARIANTS THEREOF, AND THE USE THEREOF FOR PRESENTATION ON THE CELL SURFACE

Also Published As

Publication number Publication date
NO20033796L (no) 2003-10-31
CA2438833A1 (en) 2002-10-31
MXPA03007881A (es) 2003-12-04
EP1239032A1 (en) 2002-09-11
NZ527861A (en) 2005-02-25
RU2003129265A (ru) 2005-04-10
WO2002086102A1 (en) 2002-10-31
PL367208A1 (en) 2005-02-21
EP1370640A1 (en) 2003-12-17
CN1505678A (zh) 2004-06-16
AR035761A1 (es) 2004-07-07
KR20080111172A (ko) 2008-12-22
NO20033796D0 (no) 2003-08-26
ZA200307680B (en) 2005-01-13
IL157468A0 (en) 2004-03-28
US20040265290A1 (en) 2004-12-30
US7235395B2 (en) 2007-06-26
AU2002256639B2 (en) 2006-10-19
KR20030082950A (ko) 2003-10-23
JP2004528034A (ja) 2004-09-16
RU2312892C2 (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
BR0207749A (pt) Bactérias do ácido láctico como agentes para tratar e prevenir alergias
Eliasson et al. Unloaded rat Achilles tendons continue to grow, but lose viscoelasticity
Lei et al. Effect of sonication on thermolysin hydrolysis of ovotransferrin
Karanth et al. Nature of signals that initiate the immune response during Wallerian degeneration of peripheral nerves
BRPI0516437A (pt) utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR112012012160A2 (pt) material e métodos para tratar ou prevenir doenças associadas ao her-3
KR20110060903A (ko) 지속성이 변경된 클로스트리듐 신경독
Lei et al. Activation of cerebral recovery by matrix metalloproteinase-9 after intracerebral hemorrhage
BRPI0713061A2 (pt) aplicação em alta freqüência de componente neurotóxico de toxina butolìnica
BRPI0410963B8 (pt) anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo
ATE350010T1 (de) Zusammensetzung zur topischen anwendung
Takai et al. Recombinant Der p 1 and Der f 1 with in vitro enzymatic activity to cleave human CD23, CD25 and α1-antitrypsin, and in vivo IgE-eliciting activity in mice
MXPA03001673A (es) Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
BR112014001017A2 (pt) uso de um ou mais nucleotídeos para aperfeiçoar a estabilidade de calor de uma composição aquosa de caseína micelar; composição nutricional líquida; processo para o tratamento com calor de uma composição aquosa de caseína micelar; e método para prover nutrição a uma pessoa com necessidade desta
Saravia et al. The venom of Bothrops asper from Guatemala: toxic activities and neutralization by antivenoms
BRPI0516134A (pt) neurotoxinas de clostridium para uso na cicatrização de tecidos
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
Kaya et al. The effects of epidermal growth factor on early burn‐wound progression in rats
Sozbilen et al. Neuroprotective effects of C-terminal domain of tetanus toxin on rat brain against motorneuron damages after experimental spinal cord injury
AU4152799A (en) Glycoproteins having lipid mobilising properties and therapeutic applications thereof
Wang et al. The effect of capacitively coupled (CC) electrical stimulation on human disc nucleus pulposus cells and the relationship between CC and BMP-7

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.